Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2026)

Tango Therapeutics has reported Cash & Equivalents over the past 6 years, most recently at $112.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 61.48% year-over-year to $112.3 million; the TTM value through Dec 2025 reached $112.3 million, up 61.48%, while the annual FY2025 figure was $112.3 million, 61.48% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $112.3 million at Tango Therapeutics, up from $58.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $205.0 million in Q3 2021 and troughed at $39.3 million in Q2 2025.
  • A 5-year average of $79.2 million and a median of $63.5 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 203565.03% in 2021 and later plummeted 58.65% in 2022.
  • Year by year, Cash & Equivalents stood at $145.0 million in 2021, then crashed by 58.65% to $60.0 million in 2022, then grew by 10.7% to $66.4 million in 2023, then rose by 4.74% to $69.5 million in 2024, then soared by 61.48% to $112.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for TNGX at $112.3 million in Q4 2025, $58.3 million in Q3 2025, and $39.3 million in Q2 2025.